Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Share News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

E-Therapeutics depression drug trials miss targets

Mon, 15th Feb 2016 09:45

(ShareCast News) - Drug trials results for e-Therapeutics' depression treatment were not as successful as had been hoped, sending shares in the company sharply lower.Phase IIb clinical trials of the company's ETS6103 product did not achieve the aim of matching the efficacy of existing tricyclic anti-depressant drug amitriptyline.Tested on a total of 383 patients, ETS6103 was found to be inferior to amitriptyline in its antidepressant activity, but some patients did go into remission.But e-Therapeutics said the results overall were "pleasingly similar to the profile of ETS6103 that we hoped to have" and so the AIM-listed company would carry out further examination of the results to see if ETS6103 is worth out-licensing for its potential to create fewer side-effects compared to a tricyclic antidepressant."The global antidepressant market is substantial and growing and there is an increasing need for effective and less toxic drugs," said development director Steve Self. "ETS6103's profile may offer benefit to patients who have not successfully responded to an SSRI and it may have fewer side-effects and superior tolerance when compared to a tricyclic antidepressant."We will analyse the datasets further, particularly in relation to these apparent benefits, to identify what further development and potential out licensing steps should be taken."Shares in the company fell 31% to 18p on the news by 1000 GMT on Monday.
More News
8 May 2014 10:51

e-Therapeutics Trading Up As Brain Cancer Trial To Resume Recruitment

LONDON (Alliance News) - Shares in e-Therapeutics PLC were trading higher Thursday after it said that it had been cleared by the US Food and Drug administration to resume recruiting patients for its Phase Ia study of compound ETS2101 in brain cancer. The company had previously paused recrui

Read more
7 Apr 2014 12:25

UPDATE: e-Therapeutics Appoints Steve Medlicott Chief Financial Officer

LONDON (Alliance News) - e-Therapeutics PLC Monday said that it had appointed Steve Medlicott as Chief Financial Officer, following the resignation of Daniel Elger with immediate effect, also announced Monday. Medlicott had advised the company on its GBP40 million fund-raising in 2013. Medl

Read more
7 Apr 2014 10:57

e-Therapeutics's Chief Financial Officer Daniel Elger Resigns

LONDON (Alliance News) - e-Therapeutics PLC Monday said that Daniel Elger has resigned as Chief Financial officer and a director of the company, with immediate effect. e-Therapeutics said that the company's finances will be managed on an interim basis by Paul Stockdale, who has been the com

Read more
31 Mar 2014 12:50

REPEAT: UK MIDDAY BRIEFING: Babcock JV Wins GBP7 Billion Nuclear Contract

LONDON (Alliance News) - Babcock International Group is leading the FTSE 100 higher Monday after its Cavendish Fluor Partnership joint venture was selected as the preferred bidder for a GBP7 billion nuclear plant decommissioning contract.

The joint venture with Fluo

Read more
31 Mar 2014 12:45

UK MIDDAY BRIEFING: Babcock JV Wins GBP7 Billion Nuclear Contract

LONDON (Alliance News) - Babcock International Group is leading the FTSE 100 higher Monday after its Cavendish Fluor Partnership joint venture was selected as the preferred bidder for a GBP7 billion nuclear plant decommissioning contract.

The joint venture with Flou

Read more
31 Mar 2014 10:35

UK WINNERS & LOSERS: Babcock Leads FTSE 100 Risers; Insurers Rebound

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Monday.

-------

FTSE 100 - WINNERS

Babcock International Group, up 3.5%. The company said its Cavendish Fluor Partnership has

Read more
31 Mar 2014 08:33

e-Therapeutics Rises As It Gets Good Interim Drug Trial Results

LONDON (Alliance News) - e-Therapeutics PLC Monday said it had achieved positive interim results from a UK study evaluating the safety, dosing and anti-tumour activity of its ETS2101 drug in patients with advanced solid cancer tumours. In a statement, the company said that it had completed

Read more
26 Mar 2014 13:40

UK MIDDAY BRIEFING: Government Completes 2nd Lloyds Bank Stake Sale

LONDON (Alliance News) - The UK government has raised a further GBP4.20 billion from its second sale of Lloyds Banking Group PLC shares, meaning it has now recouped GBP7.41 billion of the roughly GBP21 million that taxpayers injected into the bank during the financial crisis.<

Read more
26 Mar 2014 11:30

UK WINNERS & LOSERS: Standard Life Leads FTSE 100 Risers

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Wednesday.

-------

FTSE 100 - WINNERS

Standard Life, up 5.2%. The company has agreed to buy Ignis Asset Mana

Read more
26 Mar 2014 11:03

e-Therapeutics Gains As Recruitment For Cancer Trial Resumes

LONDON (Alliance News) - Shares in e-Therapeutics PLC jumped Wednesday morning after the biotechnology company said it has received approval from MHRA to recommence recruitment of new patients into its ETS2101 phase Ia solid tumours trial. Recruitment for the trial was temporarily paused ov

Read more
24 Jan 2014 12:41

UK MIDDAY BRIEFING: Bank Of England Now Focused On Productivity

LONDON (Alliance News) - Bank of England Governor Mark Carney Friday signaled that rising productivity will now be the key factor that decides when the central bank will start to tighten monetary policy, and any tightening will be a slow, gradual process.

In a speech at the World Ec

Read more
24 Jan 2014 11:01

e-Therapeutics Temporarily Halts Recruitment In Trial Due To Drug Supply Issue

LONDON (Alliance News) - Shares in e-Therapeutics PLC dropped 16% Friday morning after it said that it was temporarily halting recruitment into its ETS2101 cancer trials due to a drug supply issue. e-Therapeutics said that there had been a practical issue with the stored drugs for the trial

Read more
24 Jan 2014 10:58

UK WINNERS & LOSERS: Cairn Falls As Indian Tax Department Gets In Touch

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Friday. ------- FTSE 100 - WINNERS Weir Group, up 0.2%. The engineering company said it had won a USD98 million, or GBP59 million, two-year contract to provide

Read more
7 Jan 2014 08:22

AIM IN BRIEF: H&T Says Profit As Expected, But Gold Price Has Hurt

Read more
31 Oct 2013 13:36

e-Therapeutics Starts Phase IIb Trial Of Depressive Disorder Treatment

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.